Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Eric Wu

Concepts (357)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Health Care Costs
28
2022
395
3.930
Why?
Everolimus
10
2016
68
2.530
Why?
Health Resources
8
2022
120
2.380
Why?
Cost of Illness
12
2022
289
2.110
Why?
Receptor, ErbB-2
9
2016
336
1.540
Why?
Breast Neoplasms
12
2016
2150
1.410
Why?
Hyperkalemia
2
2020
26
1.250
Why?
Medication Adherence
6
2016
569
1.230
Why?
Receptors, Estrogen
3
2015
429
1.200
Why?
Receptors, Antigen, T-Cell
4
2021
703
1.170
Why?
Immunotherapy, Adoptive
2
2020
297
1.080
Why?
Health Expenditures
6
2020
185
1.050
Why?
Practice Patterns, Physicians'
4
2016
1270
1.020
Why?
Health Services
6
2016
103
0.970
Why?
United States
39
2022
13940
0.870
Why?
Receptors, Progesterone
2
2015
345
0.850
Why?
Models, Economic
2
2020
55
0.840
Why?
Hepatitis C, Chronic
2
2015
154
0.830
Why?
Antifungal Agents
4
2017
126
0.800
Why?
Lymphoma, Large B-Cell, Diffuse
2
2021
113
0.780
Why?
Middle Aged
52
2020
31080
0.750
Why?
Antineoplastic Agents
9
2016
2060
0.750
Why?
Hospital Costs
3
2020
117
0.720
Why?
Gout
2
2012
36
0.710
Why?
Retrospective Studies
31
2022
14571
0.700
Why?
Aged
38
2022
22090
0.700
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
2020
280
0.680
Why?
Nocturia
1
2019
8
0.660
Why?
Antineoplastic Combined Chemotherapy Protocols
9
2016
1573
0.660
Why?
Kaplan-Meier Estimate
10
2017
864
0.620
Why?
Proportional Hazards Models
12
2017
1210
0.610
Why?
Female
63
2021
68518
0.610
Why?
Cost-Benefit Analysis
12
2022
582
0.610
Why?
Hospitalization
13
2021
2077
0.600
Why?
Depressive Disorder, Major
3
2011
347
0.590
Why?
Candida
2
2017
35
0.580
Why?
Nutrition Surveys
1
2019
262
0.580
Why?
Proline
2
2015
78
0.580
Why?
Fluconazole
1
2017
18
0.560
Why?
Candidemia
1
2017
9
0.560
Why?
Humans
80
2022
129128
0.550
Why?
Myocardial Perfusion Imaging
1
2017
36
0.550
Why?
Male
53
2021
63202
0.540
Why?
Medicare
7
2022
724
0.540
Why?
Cardiologists
1
2017
46
0.540
Why?
Tomography, Emission-Computed, Single-Photon
1
2017
78
0.540
Why?
Fees, Pharmaceutical
3
2016
13
0.540
Why?
Prevalence
10
2020
2565
0.530
Why?
Oligopeptides
2
2015
258
0.520
Why?
Adult
41
2022
35513
0.520
Why?
Thrombolytic Therapy
1
2017
132
0.520
Why?
Insurance Claim Review
8
2017
72
0.510
Why?
Biological Therapy
1
2016
29
0.510
Why?
Antirheumatic Agents
2
2016
282
0.510
Why?
Citalopram
3
2011
34
0.490
Why?
Renal Insufficiency, Chronic
2
2020
566
0.490
Why?
Tissue Plasminogen Activator
1
2017
220
0.490
Why?
Drug Eruptions
1
2015
26
0.490
Why?
Fibrinolytic Agents
1
2017
249
0.470
Why?
Psoriasis
3
2012
92
0.470
Why?
Databases, Factual
8
2016
1279
0.460
Why?
Comparative Effectiveness Research
2
2012
151
0.460
Why?
Hypoglycemic Agents
2
2015
1217
0.460
Why?
Diphosphonates
2
2012
58
0.460
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2008
343
0.450
Why?
Physicians, Primary Care
1
2017
227
0.450
Why?
Delivery of Health Care
2
2019
894
0.450
Why?
Brain Ischemia
1
2017
306
0.440
Why?
Anemia
1
2015
161
0.440
Why?
Imidazoles
2
2012
229
0.430
Why?
Liver Neoplasms
2
2015
643
0.420
Why?
Dextroamphetamine
1
2012
3
0.400
Why?
Antiviral Agents
2
2015
706
0.400
Why?
Methylphenidate
1
2012
37
0.390
Why?
Drug Delivery Systems
1
2015
326
0.380
Why?
Drug Costs
6
2015
103
0.380
Why?
Aged, 80 and over
11
2020
7066
0.370
Why?
Pulmonary Embolism
1
2014
208
0.370
Why?
Schizophrenia
2
2006
430
0.370
Why?
Referral and Consultation
1
2017
732
0.370
Why?
Neoplasm Metastasis
6
2016
616
0.370
Why?
Fumarates
1
2011
10
0.360
Why?
Drugs, Generic
1
2011
17
0.360
Why?
Hypertension
4
2018
1243
0.360
Why?
Drug Substitution
1
2011
52
0.360
Why?
Central Nervous System Stimulants
1
2012
156
0.350
Why?
Bone Diseases
1
2011
61
0.350
Why?
Postmenopause
4
2016
370
0.350
Why?
Angiotensin Receptor Antagonists
1
2011
90
0.340
Why?
Stroke
2
2017
1067
0.340
Why?
Amides
1
2011
92
0.340
Why?
Venous Thromboembolism
1
2014
275
0.340
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2011
201
0.330
Why?
Crohn Disease
5
2012
211
0.330
Why?
Arthritis, Rheumatoid
2
2016
1109
0.330
Why?
Multiple Myeloma
1
2011
126
0.320
Why?
Diabetes Mellitus
1
2018
1004
0.320
Why?
Anticoagulants
1
2014
614
0.320
Why?
Insurance, Health
3
2011
271
0.320
Why?
Sick Leave
2
2007
14
0.320
Why?
Hyperuricemia
1
2009
45
0.310
Why?
Diabetes Mellitus, Type 2
2
2015
2437
0.310
Why?
Antibodies, Monoclonal
6
2011
1359
0.310
Why?
Disease-Free Survival
5
2016
656
0.300
Why?
Antineoplastic Agents, Hormonal
3
2016
161
0.300
Why?
Costs and Cost Analysis
7
2019
209
0.300
Why?
Heart Failure
2
2020
2158
0.300
Why?
Risk Factors
12
2017
9769
0.300
Why?
Patient Acceptance of Health Care
7
2021
767
0.290
Why?
Attention Deficit Disorder with Hyperactivity
1
2012
398
0.290
Why?
Absenteeism
2
2005
49
0.290
Why?
Uric Acid
1
2009
161
0.290
Why?
Quality of Life
8
2021
2694
0.290
Why?
Comorbidity
8
2014
1547
0.290
Why?
Insurance Claim Reporting
2
2007
23
0.280
Why?
Neoplasm Recurrence, Local
2
2015
963
0.280
Why?
Physicians
1
2015
861
0.270
Why?
Hypoglycemia
1
2012
426
0.270
Why?
Insulin
2
2015
2320
0.270
Why?
Head and Neck Neoplasms
1
2012
534
0.270
Why?
Health Status Indicators
1
2007
169
0.260
Why?
Triazoles
3
2016
152
0.260
Why?
Pentosan Sulfuric Polyester
1
2006
1
0.260
Why?
Economics, Pharmaceutical
1
2006
10
0.260
Why?
Cystitis, Interstitial
1
2006
16
0.250
Why?
Drug Resistance, Fungal
2
2017
9
0.250
Why?
Young Adult
12
2020
12389
0.240
Why?
Endometriosis
2
2017
50
0.240
Why?
Urinary Incontinence
1
2005
63
0.230
Why?
Immunoglobulin G
1
2008
846
0.230
Why?
Prostatic Neoplasms
2
2012
1013
0.220
Why?
Recurrence
3
2020
1003
0.220
Why?
Psychotic Disorders
1
2005
153
0.210
Why?
Treatment Outcome
12
2017
10227
0.210
Why?
Drug Therapy, Combination
4
2015
1013
0.210
Why?
Antibodies, Monoclonal, Humanized
7
2012
764
0.200
Why?
Population Surveillance
1
2005
428
0.190
Why?
Anti-Inflammatory Agents
3
2011
471
0.190
Why?
Bone Density Conservation Agents
2
2012
73
0.180
Why?
Giant Cell Tumor of Tendon Sheath
1
2021
5
0.180
Why?
Gout Suppressants
2
2012
20
0.180
Why?
Gastritis
1
2022
97
0.180
Why?
Biological Products
2
2016
200
0.180
Why?
Enteritis
1
2022
94
0.180
Why?
Hemophilia B
1
2021
43
0.180
Why?
Tumor Necrosis Factor-alpha
4
2009
1192
0.180
Why?
Adolescent
17
2017
20302
0.180
Why?
Hemophilia A
1
2021
75
0.170
Why?
Adenocarcinoma
1
2007
889
0.170
Why?
Voriconazole
2
2016
19
0.170
Why?
National Health Programs
1
2019
18
0.170
Why?
Eosinophilia
1
2022
205
0.170
Why?
Technology Assessment, Biomedical
1
2019
30
0.170
Why?
Regression Analysis
4
2012
984
0.160
Why?
Genetic Therapy
1
2021
293
0.160
Why?
Myelodysplastic Syndromes
1
2021
129
0.160
Why?
Microbial Sensitivity Tests
2
2017
336
0.150
Why?
Aging
1
2009
1772
0.150
Why?
Nitriles
2
2016
161
0.150
Why?
Treatment Failure
2
2017
343
0.150
Why?
Idiopathic Pulmonary Fibrosis
2
2015
628
0.150
Why?
Vital Capacity
2
2015
291
0.150
Why?
Polystyrenes
1
2018
38
0.150
Why?
Overweight
1
2022
526
0.140
Why?
4-Aminopyridine
1
2017
23
0.140
Why?
Potassium
1
2018
138
0.140
Why?
Emergency Service, Hospital
3
2014
1973
0.140
Why?
Retreatment
1
2017
70
0.140
Why?
Aspergillosis
1
2016
21
0.140
Why?
Mental Disorders
1
2005
1010
0.130
Why?
Antihypertensive Agents
2
2011
490
0.130
Why?
Administration, Intravenous
1
2017
137
0.130
Why?
Abiraterone Acetate
1
2016
14
0.130
Why?
Consumer Behavior
1
2017
68
0.130
Why?
Patient Compliance
2
2011
562
0.130
Why?
Hysterectomy
1
2017
120
0.130
Why?
Administrative Claims, Healthcare
1
2016
27
0.130
Why?
Aromatase Inhibitors
1
2016
52
0.130
Why?
Prostatic Neoplasms, Castration-Resistant
1
2016
45
0.130
Why?
Chronic Disease
3
2014
1707
0.130
Why?
Capecitabine
1
2016
47
0.130
Why?
Health Care Rationing
1
2016
58
0.130
Why?
Ambulatory Care
3
2015
506
0.120
Why?
Clinical Protocols
1
2017
254
0.120
Why?
Patient Admission
1
2017
184
0.120
Why?
Time-to-Treatment
1
2017
180
0.120
Why?
Prednisone
1
2016
236
0.120
Why?
Disability Evaluation
1
2017
291
0.120
Why?
Ki-1 Antigen
1
2015
5
0.120
Why?
International Classification of Diseases
1
2016
124
0.120
Why?
Androstadienes
1
2015
107
0.120
Why?
Logistic Models
2
2014
1979
0.120
Why?
Waiting Lists
1
2017
238
0.120
Why?
Lymphoma, Large-Cell, Anaplastic
1
2015
20
0.120
Why?
Drug Interactions
1
2016
360
0.120
Why?
Ribavirin
1
2015
92
0.120
Why?
California
2
2006
400
0.110
Why?
Cross-Sectional Studies
3
2019
5070
0.110
Why?
Drug Administration Schedule
3
2011
758
0.110
Why?
International Normalized Ratio
1
2014
47
0.110
Why?
Heparin, Low-Molecular-Weight
1
2014
29
0.110
Why?
Leukemia, Myeloid, Acute
1
2021
592
0.110
Why?
Amphotericin B
1
2014
30
0.110
Why?
Recombinant Proteins
1
2017
1284
0.110
Why?
Follow-Up Studies
5
2015
4915
0.110
Why?
Insurance, Health, Reimbursement
1
2014
96
0.110
Why?
Immunoconjugates
1
2015
102
0.110
Why?
Drug Prescriptions
1
2015
251
0.110
Why?
Constipation
1
2014
89
0.110
Why?
Pulmonary Disease, Chronic Obstructive
2
2011
953
0.110
Why?
China
1
2014
191
0.110
Why?
Mycoses
1
2014
70
0.110
Why?
Models, Theoretical
1
2017
546
0.110
Why?
Morpholines
1
2014
125
0.110
Why?
ErbB Receptors
2
2016
603
0.110
Why?
Thiophenes
1
2014
119
0.110
Why?
Recovery of Function
1
2017
648
0.100
Why?
Budgets
1
2012
14
0.100
Why?
Warfarin
1
2014
147
0.100
Why?
Pyridines
1
2016
477
0.100
Why?
Hodgkin Disease
1
2015
136
0.100
Why?
Drug Combinations
2
2011
329
0.100
Why?
Allopurinol
1
2012
61
0.100
Why?
Multivariate Analysis
4
2015
1496
0.100
Why?
Adalimumab
5
2011
44
0.100
Why?
Laparoscopy
1
2017
454
0.100
Why?
Health Status
2
2008
751
0.100
Why?
Gastrointestinal Diseases
1
2014
197
0.100
Why?
Lisdexamfetamine Dimesylate
1
2012
9
0.100
Why?
Databases as Topic
2
2009
62
0.100
Why?
Immunocompromised Host
1
2014
195
0.100
Why?
Neoplasm Staging
1
2015
1293
0.100
Why?
Estradiol
1
2015
497
0.100
Why?
Multiple Sclerosis
1
2017
437
0.090
Why?
Rivaroxaban
1
2014
254
0.090
Why?
Patient Readmission
1
2017
668
0.090
Why?
Sulfonylurea Compounds
1
2012
47
0.090
Why?
Medicaid
2
2006
437
0.090
Why?
Sirolimus
1
2012
189
0.090
Why?
Fractures, Spontaneous
1
2011
13
0.090
Why?
Spinal Cord Compression
1
2011
20
0.090
Why?
Hypercalcemia
1
2011
19
0.090
Why?
Models, Statistical
2
2012
626
0.090
Why?
Cost Sharing
1
2011
15
0.090
Why?
Communication
1
2017
840
0.090
Why?
Efficiency
2
2011
95
0.090
Why?
Japan
2
2021
98
0.090
Why?
Bone Diseases, Metabolic
1
2011
60
0.090
Why?
Antidepressive Agents, Second-Generation
1
2010
43
0.090
Why?
Bone Neoplasms
1
2012
231
0.080
Why?
Bronchodilator Agents
1
2011
245
0.080
Why?
Severity of Illness Index
4
2012
2739
0.080
Why?
Angiogenesis Inhibitors
1
2011
216
0.080
Why?
Administration, Oral
1
2012
759
0.080
Why?
Linear Models
1
2012
816
0.080
Why?
Gastrointestinal Agents
1
2009
60
0.080
Why?
Surveys and Questionnaires
3
2021
5377
0.080
Why?
Antidepressive Agents
1
2011
221
0.080
Why?
Obesity
1
2022
2863
0.080
Why?
Etanercept
1
2008
58
0.080
Why?
Blood Chemical Analysis
1
2009
96
0.080
Why?
Case-Control Studies
2
2014
3342
0.080
Why?
Time Factors
2
2017
6518
0.080
Why?
Age Distribution
3
2015
376
0.070
Why?
Receptors, Tumor Necrosis Factor
1
2008
162
0.070
Why?
Employment
2
2007
167
0.070
Why?
Clinical Trials as Topic
1
2012
1000
0.070
Why?
Digestive System Surgical Procedures
1
2008
99
0.070
Why?
Quality-Adjusted Life Years
2
2022
108
0.070
Why?
Veterans Disability Claims
1
2006
1
0.070
Why?
Private Sector
1
2006
51
0.070
Why?
Health Benefit Plans, Employee
1
2006
23
0.070
Why?
Ischemic Attack, Transient
1
2006
61
0.060
Why?
Child
4
2020
20806
0.060
Why?
Employer Health Costs
1
2005
4
0.060
Why?
Coronary Disease
1
2008
384
0.060
Why?
Metabolic Diseases
1
2007
107
0.060
Why?
Hallucinations
1
2005
30
0.060
Why?
Cohort Studies
2
2012
5407
0.060
Why?
Area Under Curve
1
2005
282
0.060
Why?
Diagnostic and Statistical Manual of Mental Disorders
1
2005
236
0.060
Why?
Carcinoma, Non-Small-Cell Lung
1
2012
1046
0.060
Why?
Metabolic Syndrome
1
2007
340
0.060
Why?
Adrenal Cortex Hormones
1
2007
519
0.050
Why?
Colorectal Neoplasms
1
2011
753
0.050
Why?
Age Factors
2
2015
3120
0.050
Why?
Data Collection
1
2006
650
0.050
Why?
Asthma
2
2007
2219
0.050
Why?
Psychiatric Status Rating Scales
1
2005
523
0.050
Why?
Lung
1
2015
3752
0.050
Why?
Drug Resistance, Neoplasm
1
2007
750
0.050
Why?
Anti-Asthmatic Agents
1
2006
373
0.050
Why?
Health Policy
1
2005
353
0.050
Why?
Interviews as Topic
1
2005
717
0.050
Why?
Glucagon-Like Peptides
1
2022
51
0.050
Why?
Mental Health Services
1
2005
400
0.040
Why?
Double-Blind Method
3
2011
1865
0.040
Why?
Asia
1
2019
58
0.040
Why?
Incidence
1
2006
2635
0.040
Why?
Administration, Inhalation
2
2011
664
0.040
Why?
Disease Progression
2
2015
2613
0.040
Why?
Potassium Channel Blockers
1
2017
35
0.040
Why?
Disease Management
2
2015
593
0.030
Why?
Models, Econometric
1
2016
34
0.030
Why?
Itraconazole
1
2016
7
0.030
Why?
Delayed-Action Preparations
1
2017
176
0.030
Why?
B-Lymphocytes
1
2020
823
0.030
Why?
Utilization Review
1
2014
37
0.030
Why?
Cardiovascular Diseases
1
2007
2024
0.030
Why?
Early Diagnosis
1
2015
236
0.030
Why?
Dose-Response Relationship, Drug
2
2009
1945
0.030
Why?
Aspergillus
1
2014
16
0.030
Why?
Hypothyroidism
1
2014
71
0.030
Why?
Cryptococcus
1
2014
8
0.030
Why?
Forced Expiratory Volume
1
2015
511
0.030
Why?
Anemia, Iron-Deficiency
1
2014
58
0.030
Why?
Peripheral Vascular Diseases
1
2014
104
0.030
Why?
Mood Disorders
1
2014
118
0.030
Why?
Acute Disease
1
2015
968
0.030
Why?
Biopsy
1
2015
1086
0.020
Why?
Risk
1
2014
856
0.020
Why?
Molecular Targeted Therapy
1
2015
387
0.020
Why?
Nervous System Diseases
1
2014
254
0.020
Why?
Matched-Pair Analysis
1
2011
43
0.020
Why?
Cetuximab
1
2011
94
0.020
Why?
Critical Care
1
2015
544
0.020
Why?
Bevacizumab
1
2011
131
0.020
Why?
Tablets
1
2010
37
0.020
Why?
Length of Stay
1
2015
1124
0.020
Why?
State Medicine
1
2009
20
0.020
Why?
Epidemiologic Methods
1
2009
74
0.020
Why?
United Kingdom
1
2009
259
0.020
Why?
Sex Factors
1
2015
1953
0.020
Why?
Injections, Subcutaneous
1
2009
145
0.020
Why?
Remission Induction
1
2009
271
0.020
Why?
Insurance Coverage
1
2010
222
0.020
Why?
Maximum Tolerated Dose
1
2009
194
0.020
Why?
Europe
1
2009
362
0.020
Why?
Odds Ratio
1
2011
1025
0.020
Why?
Probability
1
2009
308
0.020
Why?
Statistics, Nonparametric
1
2009
424
0.020
Why?
Canada
1
2009
348
0.020
Why?
Confidence Intervals
1
2008
319
0.020
Why?
Reference Values
1
2009
780
0.020
Why?
Sex Distribution
1
2008
359
0.020
Why?
Longitudinal Studies
1
2014
2716
0.020
Why?
Prognosis
1
2015
3788
0.020
Why?
Models, Biological
1
2014
1695
0.020
Why?
Randomized Controlled Trials as Topic
1
2012
1363
0.020
Why?
Tomography, X-Ray Computed
1
2015
2541
0.020
Why?
Health Status Disparities
1
2008
256
0.020
Why?
Infant
2
2007
8993
0.010
Why?
Child, Preschool
2
2007
10451
0.010
Why?
Emergency Medical Services
1
2007
550
0.010
Why?
Risk Assessment
1
2009
3260
0.010
Why?
Body Mass Index
1
2007
2266
0.010
Why?
Infant, Newborn
1
2006
5739
0.010
Why?
Wu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)